ASH 2018 | MRD highlights in myeloma from ASH 2018
Ola Landgren
Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, gives his insight into the measurable residual disease (MRD) data from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Related videos
2:43
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon
2:43
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon
2:43
Characterization of the immune impact of DARA by mass cytometry in multiple myeloma
Gareth Morgan
2:43
The MAIA study and other myeloma highlights from ASH 2018
Gareth Morgan
2:43
Characterization of exceptional responders to ASCT in multiple myeloma
Vincent Rajkumar
